Insulin is one of the most important drugs in the history of pharmaceuticals. Since the separation of active insulin from animals by the Canadian doctor Frederick Grant Banting, it has been around for nearly a hundred years and has been continuously upgraded to meet the demand for diabetes. To… Continue Reading After OI388GT terminated the trial, Novo Nordisk deployed oral insulin again, and plans to enter the human clinical clinic within three years.
Gilead Science announced on February 12 that NASH’s research drug, ASK1 inhibitor selonsertib (GS4997), missed the primary endpoint in its first phase III clinical trial (STELLAR-4). STELLAR-4 is a phase III randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of the NASH new drug selonsertib in patients… Continue Reading Gilead NASH new drug selonsertib first phase III clinical failure
On February 6, the FDA approved the introduction of Cablivi (caplacizumab-yhdp) injection developed by Sanofi’s subsidiary Ablynx for plasma exchange and immunosuppressive therapy for adult acquired thrombotic thrombocytopenic purpura (aTTP). On September 3, 2018, the European Union has approved the application for the listing of Cablivi for this indication.… Continue Reading FDA approves first Nanobody to treat acquired thrombotic thrombocytopenic purpura
On January 18th, Celgene announced a partnership with Kyn Therapeutics, a startup that is committed to developing immune systems against cancer. Kyn is an investment by Atlas Venture and OrbiMed and is headquartered in Boston. Celgene will pay Kyn a down payment of $80 million and an undisclosed equity… Continue Reading Celgene’s heavy trading
B vitamins are all coenzymes involved in the metabolism of important substances such as sugar, fat and protein, and are indispensable water-soluble vitamins for maintaining normal functions of the human body. B vitamins are easily destroyed in an alkaline environment, and the human body cannot manufacture and synthesize by… Continue Reading Summary of the efficacy of B vitamins
In recent years, the number of new drugs approved by the FDA has reached record highs. With this situation, the pricing of specialty drugs is getting higher and higher, and the prices of some new technology therapies that have not yet been approved are even more jaw-dropping. According to… Continue Reading The 20 most expensive drugs in the US pharmacy retail price in 2018
What role will technology play in the healthcare industry in 2019? For venture capitalists and others interested in the medical industry, it is critical to be able to predict the direction of industry innovation more accurately than others. Recently, MedCity News has predicted five major innovation trends affecting the… Continue Reading These 5 major innovation trends will affect the medical and health industry in 2019.
In 2006, Stanford University professor Andrew Z. Fire and University of Massachusetts Medical Professor Craigc. Mello won the 2006 Nobel Prize in Physiology/Medical for discovering RNA interference (RNAi) and their outstanding contributions in the field of gene silencing. At the time of the award, they predicted that the application… Continue Reading 2018 Top Ten RNA Therapy Company, the first place is not Moderna?
Two years ago, the University of Basel’s Don Benjanmin research team published an article in the journal Science Advance, saying that the antihypertensive drug syrosingopine (silosepine) significantly enhanced the anti-tumor efficacy of metformin, causing the medical community. Extensive discussion: Metformin plus carbazone is an anticancer drug? But the research… Continue Reading Metformin anticancer mechanism
EvaluatePharma recently released the “EP Vantage 2019 Preview” report, which uses the net present value method (NPV) to evaluate the market potential of new drugs in the world. Regarding the net present value, you can simply understand “how much is the value of a new drug asset at a… Continue Reading Outlook 2019: The world’s most valuable new drug TOP20